alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 326–350 of 375 studies published 2023 · free to read (page 14 of 15) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 375 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The influence of Area Deprivation Index on cognition in cognitively‐normal adults as measured by Principal Component Analysis of Neuropsychological Data

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2023-12-01

Our results suggest that the relationship between greater neighborhood disadvantage and poorer cognitive function are very subtle and may only be present for some, but not all, cognitive domains. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Brain PET Imaging: Frontotemporal Dementia

✓ Peer-reviewed alzhub usefulness score 39 out of 100. PET clinics 2023-01-01

Brain PET adds value in diagnosing neurodegenerative disorders, especially frontotemporal dementia (FTD) due to its syndromic presentation that overlaps with a variety of other neurodegenerative and psychiatric disorders. 18F-FDG-PET has improved sensitivity and specificity compared with structural MR imaging, with optimal diagnostic results achieved when both techniques are utilized. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Focused Ultrasound-mediated Liquid Biopsy in a Tauopathy Mouse Model

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Radiology 2023-01-31

In the 2-month-old mice, sonobiopsy significantly increased the normalized levels of plasma p-tau species compared with the conventional blood-based liquid biopsy (p-tau-181-to-mouse tau [m-tau] ratio: 1.7-fold increase, P = .006; p-tau-231-to-m-tau ratio: 1.4-fold increase, P = .048). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neurochemical Ameliorating of the Hippocampus in Dyslipidemic Alzheimer Patients Following Silymarin; a Double-Blind Placebo-Controlled Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Medical journal of the Islamic Republic of Iran 2023-11-18

Donepezil and silymarin improved lipid profile associated with increased NAA/Cr, and decreased mI/Cr, in AD patients. 4 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease Patients

✓ Peer-reviewed alzhub usefulness score 39 out of 100. The journal of prevention of Alzheimer's disease 2023-01-01

The ASURE trial design is discussed, with a particular focus on fluid biomarkers, EEG, and CFC as endpoints. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Large-scale organoid study suggests effects of trisomy 21 on early fetal neurodevelopment are more subtle than variability between isogenic lines and experiments

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in neuroscience 2023-02-03

This study examines cortical organoids generated from a panel of isogenic trisomic and disomic iPSC lines (subclones) as a model of early fetal brain development in Down syndrome (DS). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer's Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Gerontology 2023-08-22

Alzheimer's disease (AD) is one of the pathologies that the scientific world is still desperate for. 4 key findings →

Participants: 120 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Memory Alteration Test Is Correlated with Clinical, Cerebrospinal Fluid, and Brain Imaging Markers of Alzheimer Disease in Lima, Peru

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Dementia and geriatric cognitive disorders 2023-10-12

As disease-modifying therapies become available for Alzheimer's disease (AD), detection of AD in early stages of illness (mild cognitive impairment [MCI], early dementia) becomes increasingly important. 4 key findings →

Participants: 185 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Interaction between DNA methylation and neighborhood disadvantage may impact risk for cognitive decline among Mexican Americans enrolled in the Health and Aging Brain Study – Health Disparities (HABS‐HD) Cohort

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2023-12-01

The lack of significant results for moderation effects of the targeted epigenetic markers in our pilot study were likely due to the small sample size. 5 key findings →

Participants: 812 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in Traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2023-12-01

Lower diagnosed dementia rates in MA compared to TM may exacerbate racial/ethnic disparities in diagnosed dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessment for Alzheimer’s Disease Advancement Using Classification Models with Rules

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Applied Sciences 2023-11-08

Pre-diagnosis of common dementia conditions such as Alzheimer’s disease (AD) in the initial stages is crucial to help in early intervention, treatment plan design, disease management, and for providing quicker healthcare access. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterize demographics, comorbidities and co‐medications in newly diagnosed United States (US) Alzheimer’s Disease patients using Medicare claims

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2023-12-01

Extensive understanding of a drug’s real‐world target population can inform generalizability of clinical trial results and highlight unaddressed risk. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Impact of fee-revision policy for gastrostomy on its implementation among older adults with dementia in Japan

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Public health 2023-12-21

This study aimed to evaluate the impact of the policy to reduce the reimbursement fee for percutaneous endoscopic gastrostomy (PEG) on the number of PEG procedures performed among older adults with dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

At Home versus in a Nursing Home: Long-term Care Settings and Marginal Utility

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Not indexed 2023

Marginal utility of financial resources when needing long-term care, and the related incentives for precautionary savings and insurance, may vary significantly by whether one receives care at home or in a nursing home. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Health Forum 2023-02-24

This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Neurological research and practice 2023-06-29

Alzheimer´s disease is considered a neurodegenerative disease and is diagnosed by exclusion, while the detection of specific cerebrospinal fluid (CSF) biomarkers, namely amyloid-beta (Aβ) peptides Aβ1-42 (Aß42), phospho-tau (181P; P-tau), and total-tau (T-tau), has been shown to improve diagnostic accuracy. 4 key findings →

Participants: 29 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Perceptions of Hospital Care for Persons With Dementia During the COVID-19 Pandemic: A Social Media Sentiment Analysis

✓ Peer-reviewed alzhub usefulness score 35 out of 100. The Gerontologist 2023-11-07

Hospital dementia care discourse on Reddit advanced 4 negative sentiment themes: (1) fear of poor medication management, hydration, and hygiene, (2) loss of patient advocacy, (3) precipitation of advance directive discussions, and (4) delayed discharge and loss of nursing home bed. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events